6 Papers
Li Dai is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: T cell & Lymph. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
Farideh Ordikhani,Mayuko Uehara,Vivek Kasinath,Li Dai,Siawosh K. Eskandari,Baharak Bahmani,Merve Yonar,Jamil Azzi,Yousef Haik,Peter T. Sage,George F. Murphy,Nasim Annabi,Tobias Schatton,Indira Guleria,Reza Abdi +14 more
TL;DR: It is found that anti-PD-1 NPs undergo internalization by DCs in the spleen, leading to their maturation and the subsequent activation of T cells, which improves the antitumor effect of this agent in the B16-F10 murine melanoma model.
Ischemia augments alloimmune injury through IL-6-driven CD4+ alloreactivity.
Mayuko Uehara,Zhabiz Solhjou,Naima Banouni,Vivek Kasinath,Ye Xiaqun,Li Dai,Osman A. Yilmam,Mine Yilmaz,Takaharu Ichimura,Paolo Fiorina,Paulo N. Martins,Shunsuke Ohori,Indira Guleria,Omar H. Maarouf,Stefan G. Tullius,Martina M. McGrath,Reza Abdi +16 more
TL;DR: A novel pathway where IRI activates innate immunity, leading to upregulation of antigen specific alloimmunity, resulting in chronic allograft injury is described, and a clinically relevant treatment strategy to overcome the deleterious effect of IRI is described.
Characterization of CD41+ cells in the lymph node
Li Dai,Mayuko Uehara,Xiaofei Li,Brenna A. LaBarre,Naima Banouni,Takaharu Ichimura,Melissa M. Lee-Sundlov,Vivek Kasinath,Jade A. Sullivan,Heyu Ni,Francesca Barone,Silvia Giannini,Baharak Bahmani,Peter T. Sage,Nikolaos A. Patsopoulos,George C. Tsokos,C. Bromberg,Karin M. Hoffmeister,Liwei Jiang,Reza Abdi +19 more
TL;DR: CD41+Lyve1- cells of the LNs were sensitive to radiation, suggestive of their replicative nature, and FTY720 reduced their trafficking to lymph fluid, suggesting that their egress is controlled by the S1P1 pathway.
Anti-IL-6 eluting immunomodulatory biomaterials prolong skin allograft survival
Mayuko Uehara,Xiaofei Li,Amir Sheikhi,Nooshin Zandi,Nooshin Zandi,Nooshin Zandi,Brian Walker,Brian Walker,Bahram Saleh,Naima Banouni,Liwei Jiang,Farideh Ordikhani,Li Dai,Merve Yonar,Ishaan Vohra,Vivek Kasinath,Dennis P. Orgill,Ali Khademhosseini,Nasim Annabi,Reza Abdi +19 more
TL;DR: Using a highly stringent skin transplant model, the GelMA/anti- IL-6 IMB was far superior to systemic anti-IL-6 receptor treatment in prolonging skin allograft survival and its potential utility in treating patients with severe burns.
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy
Liwei Jiang,Yi-Jun Wang,Jing Zhao,Mayuko Uehara,Qingming Hou,Qingming Hou,Vivek Kasinath,Takaharu Ichimura,Naima Banouni,Li Dai,Xiaofei Li,Dale L. Greiner,Leonard D. Shultz,Xiaolong Zhang,Zhen-Yu Jim Sun,Ian Curtin,Nicholas E. Vangos,Zoe C. Yeoh,Ezekiel A. Geffken,Hyuk-Soo Seo,Ze-Xian Liu,Gregory J. Heffron,Khalid Shah,Khalid Shah,Sirano Dhe-Paganon,Reza Abdi,Reza Abdi +26 more
TL;DR: A paradigm to control cancer growth that is based on both direct tumor killing and the triggering of protective immunity is described, which permits a combination of tumor ablation, interference within the TME, and immunotherapy in one potential modality.